Live price temporarily unavailable.
Pliant Therapeutics (PLRX) is a Health Care company. Latest news and coverage below.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $57.1M | $41.8M | $7.57M | $9.69M | $1.58M | $0 | $0 |
| Growth (year over year) | — | −26.7% | −81.9% | +27.9% | −83.7% | −100.0% | — |
| Operating income | −$1.23M | −$41.6M | −$97.5M | −$127.2M | −$184.1M | −$228.4M | −$156.4M |
| Operating margin | −2.2% | −99.6% | −1288.1% | −1313.4% | −11654.7% | — | — |
| Net income | −$631.0K | −$41.5M | −$97.3M | −$123.3M | −$161.3M | −$210.3M | −$149.3M |
| Net margin | −1.1% | −99.3% | −1284.5% | −1273.3% | −10211.1% | — | — |
| EPS (diluted) | −$4.22 | −$1.95 | −$2.71 | −$2.94 | −$2.75 | −$3.47 | −$2.43 |
| Balance sheet | |||||||
| Cash and equivalents | $85.8M | $50.9M | $51.7M | $33.7M | $63.2M | $71.2M | $45.4M |
| Total assets | $119.1M | $295.5M | $221.2M | $350.6M | $512.2M | $396.9M | $225.2M |
| Total liabilities | $9.08M | $12.5M | $22.2M | $37.3M | $38.6M | $92.9M | $44.0M |
| Long-term debt | — | — | $0 | $9.93M | $10.1M | $30.2M | $0 |
| Shareholders' equity | −$76.3M | $283.1M | $199.1M | $313.3M | $473.6M | $304.1M | $181.2M |
| Cash flow | |||||||
| Operating cash flow | −$2.75M | −$37.3M | −$75.4M | −$94.6M | −$116.4M | −$155.5M | −$128.3M |
| Capital expenditure | $964.0K | $1.53M | $1.95M | $1.76M | $921.0K | $3.85M | $374.0K |
| Free cash flow | −$3.71M | −$38.8M | −$77.4M | −$96.4M | −$117.3M | −$159.4M | −$128.7M |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | — | — | — | — | — | — |
| Operating income | −$62.0M | — | −$58.9M | −$45.6M | −$28.3M | −$23.6M | −$21.8M | −$23.9M |
| Net income | −$57.8M | — | −$56.2M | −$43.3M | −$26.3M | −$23.6M | −$20.0M | −$22.4M |
| EPS (diluted) | −$0.95 | — | −$0.92 | −$0.71 | −$0.43 | −$0.37 | −$0.32 | −$0.36 |
| Balance sheet | ||||||||
| Cash and equivalents | $79.6M | $71.2M | $91.9M | $86.8M | $93.7M | $45.4M | $22.2M | $24.9M |
| Total assets | $445.7M | $396.9M | $344.8M | $299.8M | $276.6M | $225.2M | $202.6M | $189.9M |
| Total liabilities | $99.8M | $92.9M | $87.6M | $79.7M | $76.3M | $44.0M | $37.4M | $43.0M |
| Long-term debt | $30.1M | $30.2M | $30.3M | $30.4M | $30.4M | $0 | $0 | $0 |
| Shareholders' equity | $345.8M | $304.1M | $257.2M | $220.1M | $200.3M | $181.2M | $165.2M | $146.9M |
| Cash flow | ||||||||
| Operating cash flow | −$32.3M | — | −$48.9M | −$40.6M | −$21.1M | −$17.8M | −$19.2M | −$12.8M |
| Capital expenditure | $896.0K | — | $262.0K | $112.0K | $0 | $0 | $0 | $0 |
| Free cash flow | −$33.2M | — | −$49.1M | −$40.7M | −$21.1M | −$17.8M | −$19.2M | −$12.8M |
From Pliant Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Pliant Therapeutics in our feed yet.